The FDA has approved a new targeted breast cancer therapy for patients with specific genomic mutations, following successful results from the VIKTORIA-1 trial.
A new prediction market now allows traders to bet on FDA approval timelines and clinical trial outcomes, signaling a major shift in healthcare finance.
A landmark study finds the Apollo wearable increases sleep by 46 minutes nightly using haptic vibro-acoustic stimulation to balance the nervous system.
New clinical trial data confirms FLASH radiotherapy effectively reduces cancer pain, offering a faster, safer treatment path with minimal healthy tissue damage.
Discover how the U.S. is strategically evolving to maintain global leadership in biomedical innovation through research, talent, and supply chain security.
The FDA has approved Lipfendra, the first oral PCSK9 inhibitor. Learn how this breakthrough medication is set to transform cardiovascular disease care.
Explore the latest in clinical trial betting markets and Merck’s breakthrough cholesterol drug development in this insightful pharmaceutical industry update.
The FDA has approved the first oral PCSK9 inhibitor for high cholesterol, offering a needle-free alternative to manage LDL levels and prevent heart disease.
The clinical analytics market is set for a massive 27.9% CAGR growth. Discover how big data, AI, and EHR integration are transforming modern healthcare.
Kalshi enters the biotech sector with new prediction markets for clinical trial outcomes. Discover the implications for investors and the medical industry.